Clinicians are now prescribing GLP-1 receptor agonists for conditions that have nothing to do with weight loss or blood sugar control, and the list is growing fast. In the past eighteen months alone, the FDA has approved these drugs for obstructive sleep apnea, chronic kidney disease, cardiovascular risk reduction, and fatty liver disease. A cardiologist writing a semaglutide prescription for a patient with heart disease and no diabetes would have raised eyebrows in 2022. Today, it reflects the standard of care. For those of us focused on brain health and dementia, this expansion matters on multiple levels.
GLP-1 drugs are now being tested in Alzheimer’s and Parkinson’s disease, with mixed but instructive results. They are also showing striking associations with reduced substance use disorders, a growing concern among older adults and their caregivers. This article covers what the FDA has actually approved, what the clinical trials show for neurological conditions specifically, where the evidence falls short, and what families navigating dementia care should realistically expect from this drug class going forward. The shift from “weight loss injection” to “multi-organ therapeutic” did not happen overnight, but the pace of new approvals in 2024 and 2025 has been remarkable. Understanding which uses are backed by rigorous trial data and which remain speculative is critical for anyone making treatment decisions for themselves or a loved one.
Table of Contents
- What Is Driving Clinicians to Prescribe GLP-1 Drugs Beyond Obesity and Diabetes?
- What the Alzheimer’s Trials Actually Showed and Why the Results Were Disappointing
- The Addiction Connection and Why It Matters for Dementia Caregivers
- Comparing FDA-Approved GLP-1 Uses and What Each Means for Older Adults
- Pending Approvals, Pipeline Drugs, and Where the Evidence Is Still Thin
- What Families Managing Dementia Should Ask Their Clinician
- Where GLP-1 Research Is Headed for Brain Health
- Conclusion
- Frequently Asked Questions
What Is Driving Clinicians to Prescribe GLP-1 Drugs Beyond Obesity and Diabetes?
The short answer is that large-scale clinical trials keep revealing benefits in organ systems far removed from the gut and pancreas. GLP-1 receptors are not confined to metabolic tissues. They are expressed in the heart, kidneys, brain, and vasculature, which means these drugs have biological plausibility for effects well beyond appetite suppression. When the FLOW trial involving 3,533 patients across 28 countries demonstrated a 24 percent lower risk of kidney disease progression and cardiovascular death in people with type 2 diabetes and chronic kidney disease, it was stopped early because withholding the drug from the placebo group became ethically difficult. That trial led directly to the FDA approving Ozempic for CKD in January 2025. The pattern has repeated across other conditions.
The ESSENCE trial showed that 62.7 percent of patients on semaglutide achieved resolution of metabolic dysfunction-associated steatohepatitis, compared to 34.1 percent on placebo. By August 2025, Wegovy became the first GLP-1 approved for MASH with liver fibrosis. Meanwhile, Zepbound earned approval for obstructive sleep apnea in December 2024, the first medication ever approved for that condition, after trial participants lost 18 to 20 percent of their body weight and many saw their sleep apnea improve to mild severity or full remission. What makes this different from off-label enthusiasm is that these are FDA-approved indications backed by Phase 3 data. Clinicians are not simply guessing that the drugs might help. They are following evidence that meets regulatory thresholds, and insurers are beginning to cover these uses accordingly. CMS launched a voluntary model specifically to expand access to GLP-1 medicines for Medicare and Medicaid beneficiaries, reflecting how far the clinical consensus has moved beyond the original obesity framing.
What the Alzheimer’s Trials Actually Showed and Why the Results Were Disappointing
For families dealing with dementia, the most anticipated GLP-1 research involved semaglutide in Alzheimer’s disease. The results were not what anyone hoped for. The Phase 3 EVOKE and EVOKE+ trials enrolled 3,808 participants with early Alzheimer’s and found that semaglutide failed to slow cognitive decline compared to placebo. this was a significant setback, particularly because observational data and smaller studies had generated real optimism about the drug class. However, the failure does not close the book on GLP-1s and neurodegeneration. A smaller trial of liraglutide in Alzheimer’s patients showed some signs of slowed cognitive decline, suggesting that different GLP-1 molecules, dosing strategies, or patient populations might yield different outcomes. In Parkinson’s disease, the picture is similarly mixed.
The LIXIPARK trial of lixisenatide showed promise, while results for exenatide and liraglutide in Parkinson’s were inconclusive. Researchers are now pivoting to new approaches, including higher doses, earlier intervention in the disease course, and combination therapies. The honest takeaway for caregivers and patients is this: if someone is marketing a GLP-1 drug as a dementia treatment today, they are getting ahead of the science. The biological rationale remains sound, since GLP-1 receptors in the brain are involved in neuroprotection and inflammation modulation, but the clinical proof is not there yet. Families should be wary of clinics offering these drugs specifically for cognitive decline outside of a clinical trial setting. The risk is not just financial. Taking an injectable medication with real side effects for an unproven neurological benefit is a trade-off that currently does not favor the patient.
The Addiction Connection and Why It Matters for Dementia Caregivers
One of the most unexpected findings in GLP-1 research has direct relevance to brain health. A large observational study of more than 600,000 patients found that GLP-1 use was associated with 50 percent fewer substance-related deaths, 39 percent fewer drug overdoses, and 26 percent fewer drug-related hospitalizations. The reductions appeared across alcohol, opioids, cocaine, cannabis, and nicotine. A study published in JAMA Psychiatry in early 2025 went further, showing that semaglutide reduced craving and alcohol consumption in people with alcohol use disorder. This matters in dementia care more than most people realize. Alcohol use disorder in older adults is underdiagnosed and accelerates cognitive decline.
Caregivers themselves face elevated rates of substance use as a coping mechanism. If GLP-1 drugs genuinely modulate the brain’s reward circuitry, and more than a dozen additional trials are now underway to test this, the implications extend well beyond addiction medicine. They suggest that these drugs interact with the brain in ways that current neurodegenerative disease trials may not have adequately captured. The limitation is that most of the addiction evidence remains observational. The 600,000-patient study was not a randomized controlled trial, which means confounding factors could explain part of the association. People who are prescribed GLP-1 drugs tend to be more engaged with the healthcare system, which itself correlates with better outcomes. Still, the magnitude of the findings, a halving of substance-related deaths, is difficult to dismiss entirely, and the mechanistic story involving GLP-1 receptors in the brain’s reward pathways is biologically coherent.
Comparing FDA-Approved GLP-1 Uses and What Each Means for Older Adults
Not all GLP-1 approvals carry equal weight for people over 65. The cardiovascular risk reduction indication is arguably the most broadly relevant. Wegovy was approved in 2024 to reduce cardiovascular risk in adults with heart disease who are overweight or obese, and in December 2025, the FDA approved an oral semaglutide pill for the same purpose. For older adults already managing heart disease, this creates a new therapeutic option that does not require injections, which matters significantly for adherence and quality of life. The chronic kidney disease approval is similarly important for aging populations. CKD is common in older adults and frequently co-occurs with type 2 diabetes. The 24 percent reduction in kidney disease progression seen in the FLOW trial is clinically meaningful, particularly because CKD itself is an independent risk factor for cognitive decline and dementia.
Treating the kidneys may indirectly benefit the brain, though this remains a hypothesis rather than a proven connection. The obstructive sleep apnea approval deserves special attention from a brain health perspective. Untreated OSA is now well-established as a risk factor for Alzheimer’s disease and vascular dementia. The approval of Zepbound for moderate-to-severe OSA in adults with obesity, with new prescriptions among OSA patients increasing 16 percent in the first six months after approval, means that a significant dementia risk factor now has a pharmaceutical treatment option. However, this approval is specifically for patients with obesity. If someone has sleep apnea but is not obese, Zepbound is not indicated, and CPAP remains the frontline therapy. The drug does not treat the airway mechanics of OSA directly. It works through weight loss, which reduces the tissue burden on the airway.
Pending Approvals, Pipeline Drugs, and Where the Evidence Is Still Thin
Two pending FDA decisions are worth watching. Novo Nordisk has resubmitted Wegovy for heart failure with preserved ejection fraction in adults with obesity. The pooled STEP-HFpEF data showed that 32.6 percent of semaglutide patients improved by at least one NYHA functional class versus 21.5 percent on placebo. Real-world data showed GLP-1s reduced adverse heart failure events by 40 percent in HFpEF patients. Separately, semaglutide and tirzepatide reduced hospitalization and mortality risk by 42 percent and 58 percent, respectively, compared to sitagliptin. If approved, this would be meaningful for older adults with heart failure, a population that overlaps considerably with those at risk for vascular cognitive impairment. Ozempic has also been submitted to the FDA for peripheral artery disease in patients with type 2 diabetes. The STRIDE Phase 3b trial showed semaglutide improved maximum walking distance by 13 percent versus placebo after 52 weeks.
A decision is expected in 2025 or 2026. PAD affects mobility and independence in older adults, and reduced physical activity is itself a dementia risk factor. The chain of causation is indirect, but the clinical relevance is real. The warning here is about pipeline enthusiasm outrunning evidence. As of 2026, GLP-1 receptor agonists are under active clinical investigation for prediabetes, diabetic retinopathy, inflammatory bowel disease, type 1 diabetes, arthritis, and polycystic kidney disease. The STEP-9 trial for knee osteoarthritis showed promising results, with semaglutide producing 13.7 percent weight loss and a 41.7-point reduction in knee pain scores versus 27.5 points for placebo. But “under investigation” is not the same as “proven effective.” Patients and families should not assume that a drug being studied for a condition means it works for that condition. Clinical trials fail more often than they succeed, as the Alzheimer’s results demonstrated.
What Families Managing Dementia Should Ask Their Clinician
If a loved one with dementia is also managing obesity, type 2 diabetes, heart disease, CKD, or sleep apnea, asking about GLP-1 therapy for those specific conditions is entirely reasonable. The drug may not help cognition directly, but treating cardiovascular risk factors, kidney disease, and sleep apnea can slow the trajectory of vascular contributions to cognitive impairment. The question to pose is not “will this help their memory” but rather “could treating this comorbidity reduce the overall burden on their brain.” Families should also be aware of practical barriers.
GLP-1 drugs remain expensive, and insurance coverage varies by indication. A prescription written for cardiovascular risk reduction may be covered while the same drug prescribed off-label for a different purpose may not be. Medicare coverage is expanding through the CMS voluntary access model, but the landscape is uneven. Nausea, the most common side effect, can be particularly problematic in older adults who are already eating poorly or losing weight due to dementia-related changes in appetite and behavior.
Where GLP-1 Research Is Headed for Brain Health
The failure of semaglutide in the EVOKE trials has not ended interest in GLP-1s for neurodegeneration. Researchers are now exploring whether earlier intervention, before significant amyloid accumulation, might produce different results. There is also growing interest in dual and triple agonist molecules that target GLP-1 receptors alongside GIP and glucagon receptors, which may have stronger neuroprotective effects. Tirzepatide, a dual GLP-1/GIP agonist, is the most prominent example already on the market, though it has not yet been tested specifically in Alzheimer’s trials.
The broader trajectory is clear. GLP-1 drugs are becoming a platform technology in medicine, much as statins did in the 1990s when they expanded from cholesterol management into cardiovascular prevention more broadly. For brain health, the most promising near-term path may not be direct neuroprotection but rather aggressive treatment of the metabolic, cardiovascular, and sleep-related risk factors that drive cognitive decline. The drugs we have today are already approved for several of those risk factors. Using them well may turn out to matter more for dementia prevention than any single Alzheimer’s-specific trial result.
Conclusion
The expansion of GLP-1 drugs beyond obesity and diabetes represents one of the most significant shifts in prescribing patterns in recent years. FDA approvals now cover obstructive sleep apnea, chronic kidney disease, cardiovascular risk reduction, and fatty liver disease, with heart failure and peripheral artery disease decisions pending. For brain health, the direct evidence in Alzheimer’s disease has been disappointing, but the indirect benefits of treating comorbid conditions that contribute to cognitive decline are substantial and increasingly well-documented.
Families navigating dementia care should view GLP-1 drugs not as a cognitive treatment but as a tool for managing the constellation of conditions that worsen brain health over time. Conversations with clinicians should focus on specific, approved indications relevant to the patient’s full medical picture. The science is moving quickly, with ongoing trials in addiction, arthritis, and multiple other conditions, but the strongest decisions will continue to be the ones grounded in what the evidence actually supports today rather than what headlines promise for tomorrow.
Frequently Asked Questions
Are GLP-1 drugs approved to treat Alzheimer’s or dementia?
No. Semaglutide failed to slow Alzheimer’s progression in the Phase 3 EVOKE and EVOKE+ trials involving 3,808 participants. While a smaller liraglutide trial showed some positive signals, no GLP-1 drug is approved or recommended for dementia treatment. Research is continuing with modified approaches.
Can GLP-1 drugs help with alcohol or substance use problems in older adults?
Observational evidence is promising. A study of over 600,000 patients found GLP-1 use was associated with 50 percent fewer substance-related deaths, and a JAMA Psychiatry study showed semaglutide reduced alcohol craving. However, these drugs are not yet approved for addiction, and more than a dozen randomized trials are still underway.
Does the sleep apnea approval matter for dementia risk?
Potentially, yes. Untreated obstructive sleep apnea is a recognized risk factor for Alzheimer’s and vascular dementia. The FDA approved Zepbound for moderate-to-severe OSA in adults with obesity in December 2024. Treating OSA may reduce one contributor to cognitive decline, though direct evidence linking GLP-1 treatment of OSA to dementia prevention does not yet exist.
Will Medicare cover GLP-1 drugs for these newer uses?
Coverage is expanding. CMS launched a voluntary model to broaden access to GLP-1 medicines for Medicare and Medicaid beneficiaries. However, coverage depends on the specific approved indication and varies by plan. Prescriptions written for FDA-approved uses like cardiovascular risk reduction or CKD are more likely to be covered than off-label uses.
Are there risks to using GLP-1 drugs in elderly patients with dementia?
Yes. Nausea and reduced appetite are common side effects that can worsen malnutrition in patients who are already eating poorly due to dementia. Weight loss, while beneficial for obesity-related conditions, can be harmful in frail elderly patients. Any GLP-1 prescription for an older adult with dementia should involve careful monitoring of nutritional status and weight.
What GLP-1 related approvals are expected next?
The FDA is reviewing Wegovy for heart failure with preserved ejection fraction in adults with obesity, and Ozempic for peripheral artery disease in patients with type 2 diabetes. Both conditions are relevant to older adults and overlap with populations at risk for cognitive decline. Decisions are expected in 2025 or 2026.
